CDC, Unexplained immunodeficiency and opportunistic infections in infants—New York, New Jersey, California, MMWR, Dec. 17, 1982, 31: 665–67.
10.
CDC, Prevention of acquired immune deficiency syndrome (AIDS): Report of interagency recommendations, MMWR, March 4, 1983, 32: 101–4.
11.
Id.: 101.
12.
CDC, Acquired immunodeficiency syndrome (AIDS): Precautions for health-care workers and allied professionals, MMWR, Sept. 2, 1983, 32: 450–52.
13.
CDC, Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome, MMWR, July 13, 1984, 33: 377–79.
14.
Subcommittee of International Committee for the Taxonomy of Viruses, Human immunodeficiency viruses (letter to the editor), Science, May 9, 1986, 232: 697.
15.
CDC, Provisional Public Health Service interagency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome, MMWR, Jan. 11, 1985, 34: 1–5.
CDC, World Health Organization workshop: Conclusions and recommendations on acquired immunodeficiency syndrome, MMWR, May 17, 1985, 34: 275–76.
19.
CDC, Testing donors of organs, tissues, and semen for antibody to human T-lymphotropic virus type III/lymphadenopathy-associated virus, MMWR, May 24, 1985, 34: 294.
20.
StewartGJ, Transmission of human T-cell lymphotrop ic virus type III (HTLV-III) by artificial insemination by donor, Lancet1985, ii: 581–84.
21.
Associated Press, Women tested for AIDS negative, Jan. 10, 1986 (press release available on NEXIS).
22.
American Hospital Association, Management of HTLV-III/LAV infection in the hospital, rev. ed., 1986. See also Associated Press, Health organization recommends donated body parts be screened for AIDS, Dec. 10, 1985 (press release available on NEXIS).
23.
Liver donor exposed to AIDS, New York Times, Jan. 9, 1986; Associated Press, Hospital officials say liver donor has AIDS antibodies, Jan. 8, 1986 (press release available on NEXIS); United Press International, Transplant organs contaminated with AIDS virus, August 29, 1986 (press release available on NEXIS).
24.
CDC, Education and foster care of children infected with human T-lymphotropic virus type III/lymphadenopathyassociated virus, MMWR, Aug. 30, 1985, 34: 517–21.
25.
See, Board of Education of City of Plainfield v. Cooperman, no. A-45/46 (Sup. Ct. of N.J., April 15, 1987); Application of Dist. 27 Community School v. Board of Education of City of New York, no. 14940/85 (Queens County Super. Ct., Feb. 11, 1986). See also Goldberg, United Press International, AIDS outcry continues, Sept. 23, 1986 (press release available on NEXIS); Indiana teen with AIDS returns to school, American Medical News, April 25, 1986, at 10; United Press International, Appeals court hears AIDS case, Jan. 7, 1986 (press release available on NEXIS); Carroll, Associated Press, Federal judge declines to rule in AIDS schoolboy case, Aug. 16, 1985 (press release available on NEXIS); and Strauss, Associated Press, AIDS victim's suit seeks injunction against school, August 8, 1985 (press release available on NEXIS).
26.
20 U.S.C.A. §§1401–54 (West 1978 and Supp. 1986).
27.
29 U.S.C.A. §794 (West 1985 and Supp. 1985).
28.
20 U.S.C.A. §1232g (West 1978 and Supp. 1986).
29.
See, Board of Education of City of Plainfield and Application of Dist. 27 Community School Board, supra note 25.
30.
CDC, Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace, MMWR, Nov. 15, 1986, 34: 681–86, 691–95.
31.
Lewin, Business and the law: AIDS and job discrimination, New York Times, April 15, 1986, at D2, col. 1.
32.
Workplace recommendations, supra note 30, at 694.
33.
CDC, Recommendations for preventing transmission of infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus during invasive procedures, MMWR, April 11, 1986, 35: 221–23.
34.
Workplace guidelines, supra note 30, at 685–86.
35.
CDC, Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome, MMWR, Dec. 6, 1985, 34: 721–26, 731–32.
36.
CDC, Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associared virus, MMWR, March 14, 1986, 35: 152–55.
37.
CDC, Immunization of children infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus, MMWR, Sept. 26, 1986, 34: 595–98, 603–6.
38.
CDC, Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection, MMWR, April 11, 1986, 35: 231–33.
39.
CDC, The safety of hepatitis B virus volume, MMWR, March 18, 1983, 32:134–36; CDC, Hepatitis B vaccine: Evidence confirming lack of AIDS transmission, MMWR, Dec. 14, 1984, 33: 685–87.
40.
CDC, Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotropic virus type III/lymphadenopathy-associated virus, MMWR, July 18, 1986. 35: 448–52.
41.
Recommended infection-control practices for dentistry, MMWR, April 18, 1986, 35: 237–42.
42.
CDC, Recommendations for preventing possible transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus from tears, MMWR, Aug. 30, 1985, 34: 533–34.
43.
CDC, Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus, MMWR, June 13, 1986, 35: 376–78.
44.
42 U.S.C.A. §241(a)(1) (West 1982 and Supp. 1987).
45.
CurranWGostinLClarkM, Acquired immunodeficiency syndrome: Legal and regulatory policy, report to U.S. Public Health Service pursuant to contract #282-86-0032, at pp. 379–81.